Published in Prostate Cancer on October 12, 2011
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer (ARMOR1) | NCT00959959
Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer. J Med Chem (2013) 1.11
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer. Biomedicine (Taipei) (2014) 0.84
NMR WaterLOGSY Reveals Weak Binding of Bisphenol A with Amyloid Fibers of a Conserved 11 Residue Peptide from Androgen Receptor. PLoS One (2016) 0.75
Translating the histone code. Science (2001) 56.77
Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature (1997) 44.55
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell (2004) 21.30
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
Epigenetics in cancer. N Engl J Med (2008) 17.36
HDAC6 is a microtubule-associated deacetylase. Nature (2002) 12.76
The development of androgen-independent prostate cancer. Nat Rev Cancer (2001) 11.88
The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev (2000) 11.65
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol (2005) 10.48
Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer (2001) 9.12
LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature (2005) 8.53
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32
Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev (1997) 6.71
Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev (2006) 6.32
A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res (2009) 6.15
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol (2010) 6.04
HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell (2005) 6.00
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res (2007) 5.97
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol (2010) 5.86
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A (2010) 5.59
Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A (2003) 5.56
SUMO--nonclassical ubiquitin. Annu Rev Cell Dev Biol (2000) 5.37
Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J (2000) 5.22
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet (2000) 5.03
Formation of the androgen receptor transcription complex. Mol Cell (2002) 4.93
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood (2006) 4.92
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem (2005) 4.62
Mechanisms of androgen-refractory prostate cancer. N Engl J Med (2004) 4.49
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol (2004) 4.25
Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol (2007) 3.89
Modification in reverse: the SUMO proteases. Trends Biochem Sci (2007) 3.84
Purification and functional characterization of the human N-CoR complex: the roles of HDAC3, TBL1 and TBLR1. EMBO J (2003) 3.72
Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell (2006) 3.16
Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc Natl Acad Sci U S A (2000) 2.79
Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem (1991) 2.79
An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell (2007) 2.75
Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med (2000) 2.65
Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem (2000) 2.60
Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate (2004) 2.49
JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc Natl Acad Sci U S A (2007) 2.45
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics (2010) 2.26
Active maintenance of mHDA2/mHDAC6 histone-deacetylase in the cytoplasm. Curr Biol (2000) 2.21
Cloning and characterization of a histone deacetylase, HDAC9. Proc Natl Acad Sci U S A (2001) 2.19
Identification of the enzyme required for activation of the small ubiquitin-like protein SUMO-1. J Biol Chem (1999) 2.18
Increasing the complexity of coactivation in nuclear receptor signaling. Cell (1999) 2.09
Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol (2007) 2.09
Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem (2002) 2.01
The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol Cell Biol (1999) 2.00
Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain. J Biol Chem (1999) 2.00
Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS Biol (2004) 1.91
Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem (1999) 1.87
Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol (2004) 1.86
Molecular regulation of androgen action in prostate cancer. J Cell Biochem (2006) 1.81
Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem (2002) 1.80
Nuclear receptor structure: implications for function. Annu Rev Physiol (2007) 1.78
The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Mol Cell Biol (1999) 1.70
CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol (2010) 1.70
Targeting histone deacetylase in cancer therapy. Med Res Rev (2006) 1.69
Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res (2009) 1.68
The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int (2003) 1.64
Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol (1997) 1.63
The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor. Mol Endocrinol (2005) 1.60
Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther (2008) 1.59
The human androgen receptor: domain structure, genomic organization and regulation of expression. J Steroid Biochem (1989) 1.58
Hsp90 regulates androgen receptor hormone binding affinity in vivo. J Biol Chem (1996) 1.56
Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J Biol Chem (2002) 1.56
Selective DNA binding by the androgen receptor as a mechanism for hormone-specific gene regulation. J Steroid Biochem Mol Biol (2001) 1.53
Post-translational modifications of steroid receptors. Biomed Pharmacother (2006) 1.44
Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells. J Biol Chem (2006) 1.43
Minireview: Alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol (2011) 1.43
Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology (1989) 1.42
Selective DNA recognition by the androgen receptor as a mechanism for hormone-specific regulation of gene expression. Mol Genet Metab (2003) 1.37
Mechanism of antiandrogen action: key role of hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry (2002) 1.34
The contribution of different androgen receptor domains to receptor dimerization and signaling. Mol Endocrinol (2008) 1.32
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther (2007) 1.32
Two catalytic domains are required for protein deacetylation. J Biol Chem (2005) 1.31
Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility. J Cell Biochem (2006) 1.31
Androgen receptor decoy molecules block the growth of prostate cancer. Proc Natl Acad Sci U S A (2007) 1.27
Site of action of low dose ketoconazole on androgen biosynthesis in men. J Clin Endocrinol Metab (1983) 1.27
HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. J Biol Chem (2009) 1.26
Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther (2005) 1.24
Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc Natl Acad Sci U S A (2009) 1.23
Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends Cell Biol (2005) 1.20
Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis. J Med Chem (1995) 1.15
Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Cancer Res (2007) 1.15
Sintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the N-terminus of the androgen receptor in prostate cancer cells. Org Lett (2008) 1.15
HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer. Mol Endocrinol (2009) 1.15
The amino terminus of the human AR is target for corepressor action and antihormone agonism. Mol Endocrinol (2002) 1.15
Interplay between two hormone-independent activation domains in the androgen receptor. Cancer Res (2006) 1.10
Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function. Mol Cancer Ther (2008) 1.04
Potentiation of androgen receptor transcriptional activity by inhibition of histone deacetylation--rescue of transcriptionally compromised mutants. J Endocrinol (2004) 1.03
Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells. Mol Cancer Res (2006) 1.02
Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro. Mol Cancer Ther (2008) 0.99
Epigenetic regulation of androgen receptor signaling in prostate cancer. Epigenetics (2010) 0.92
Results Of A Dutch Cost-Effectiveness Model Of Radium-223 In Comparison To Cabazitaxel, Abiraterone, And Enzalutamide In Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Docetaxel. Value Health (2015) 0.91
Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer (1997) 0.91
Molecular chaperones and subcellular trafficking of steroid receptors. J Steroid Biochem Mol Biol (1998) 0.90
Quality of life issues relating to endocrine treatment options. Eur Urol (1999) 0.86
Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell (2006) 3.16
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem (2005) 1.80
CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol (2010) 1.70
Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther (2008) 1.59
A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells. J Med Chem (2005) 1.33
Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. Bioorg Med Chem (2007) 1.20
Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer. J Med Chem (2013) 1.11
Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem (2007) 1.07
Potent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent. Bioorg Med Chem (2008) 1.03
Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro. Mol Cancer Ther (2008) 0.99
17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response. Mol Cancer Ther (2008) 0.99
Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells. Cancer Res (2006) 0.98
Autophagy inhibition synergistically enhances anticancer efficacy of RAMBA, VN/12-1 in SKBR-3 cells, and tumor xenografts. Mol Cancer Ther (2012) 0.92
First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines. Oncotarget (2014) 0.88
Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy. J Med Chem (2003) 0.87
Murine toxicology and pharmacokinetics of novel retinoic acid metabolism blocking agents. Cancer Chemother Pharmacol (2007) 0.87
Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy. Drug Metab Dispos (2010) 0.82
Synthesis of novel C17 steroidal carbamates. Studies on CYP17 action, androgen receptor binding and function, and prostate cancer cell growth. Steroids (2008) 0.82
Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model. J Steroid Biochem Mol Biol (2004) 0.81
Novel, potent anti-androgens of therapeutic potential: recent advances and promising developments. Future Med Chem (2010) 0.81
First pharmacophore-based identification of androgen receptor down-regulating agents: discovery of potent anti-prostate cancer agents. Bioorg Med Chem (2007) 0.81
A new simple and high-yield synthesis of 5α-dihydrotestosterone (DHT), a potent androgen receptor agonist. Steroids (2012) 0.80
Murine toxicology and pharmacokinetics evaluation of retinoic acid metabolism blocking agent (RAMBA), VN/12-1. Cancer Chemother Pharmacol (2012) 0.78
Synthesis and evaluation of novel 17-indazole androstene derivatives designed as CYP17 inhibitors. Steroids (2007) 0.77
Anti-tumor effects of a novel retinoic acid metabolism blocking agent VN/14-1 in the N-methyl-N-nitrosourea-induced rat mammary carcinoma model and its effects on the uterus. Breast Cancer Res Treat (2011) 0.76
First chemical feature-based pharmacophore modeling of potent retinoidal retinoic acid metabolism blocking agents (RAMBAs): identification of novel RAMBA scaffolds. Eur J Med Chem (2011) 0.75
Pharmacokinetics of novel inhibitors of androgen synthesis after intravenous administration in mice. Cancer Chemother Pharmacol (2003) 0.75
Targeting of protein translation as a new treatment paradigm for prostate cancer. Curr Opin Oncol (2017) 0.75